SCHEMBL12192471

SCHEMBL12192471

C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1CC(O)(OC(=O)N2Cc3cccc(F)c3C2)[C@@H]2CC/C=C/C[C@H](NC(=O)OC(C)(C)C)C(=O)N21)C(=O)NS(=O)(=O)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12192455 0.87 — —
SCHEMBL12192505 0.86 — —
SCHEMBL12192481 0.81 — —
SCHEMBL8050931 0.78 — —
SCHEMBL883258 0.75 CYP3A4 (0.50) —
SCHEMBL13624787 0.75 CYP3A4 (0.47) —
SCHEMBL4925753 0.75 CYP3A4 (0.47) —
SCHEMBL16263090 0.75 CYP3A4 (0.47) —
SCHEMBL12192480 0.74 — —
SCHEMBL12105550 0.73 CYP3A4 (0.46) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030307-B2 Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease ENANTA PHARMACEUTICALS, INC. (US) 2011-10-04 — — US disclosed
Send feedback